Progress on the risk factors of human immunodeficiency virus-1 associated neurocognitive disorder

doi:10.3877/cma.j.issn.1674-1358.2019.03.001

Abstract

Abstract:

Human immunodeficiency virus (HIV) infects human peripheral blood, which also invade the central nervous system (CNS) and trigger HIV-1 associated neurocognitive disorder (HAND), mainly manifested in inattention, feelings indifferent and memory disorders, which could lead to inconvenience for daily work and life of patients. According to the degree of neurocognitive impairment, HAND is divided into three types: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HAD). HAND has become an essential chronic central nervous system complication of patients with acquired immunodeficiency syndrome (AIDS). Patients with AIDS have undergone combined antiretroviral therapy (cART). After the inhibition of systemic viral replication, the number of patients complicated with severe HIV-related dementia decreased significantly, and with prolongation of survival period. At present, the pathogenesis of HAND is not clear, and the related risk factors need to be furtherly explored. In this paper, the research progress of risk factors related to HAND is reviewed, which provides a new idea for the diagnosis and pathogenesis of HAND.

Key words: Human immunodeficiency virus, Neurocognitive disorder, Risk factor, Age, Genetic phenomena

Haijie Tang, Sisi Liu, Fujun Jin, Yongmei Fu, Jun Dong. Progress on the risk factors of human immunodeficiency virus-1 associated neurocognitive disorder[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(03): 177-180.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.03.001

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I03/177

References 33

[1]	Singer EJ, Valdes-Sueiras M, Commins D, et al. Neurologic presentations of AIDS[J]. Neurol Clin,2010,28(1):253-275.
[2]	Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review[J]. AIDS,2011,25(5):561-575.
[3]	Sacktor N, Nakasujja N, Skolasky RL, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda[J]. Clin Infect Dis,2009,49(5):780-786.
[4]	Boivin MJ, Ruel TD, Boal HE, et al. HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children[J]. AIDS,2010,24(8):1163-1170.
[5]	Cole JH, Underwood J, Caan MW, et al. Increased brain-predicted aging in treated HIV disease[J]. Neurology,2017,88(14):1349-1357.
[6]	Wade BS, Valcour VG, Wendelken-Riegelhaupt L, et al. Mapping abnormal subcortical brain morphometry in an elderly HIV+ cohort[J]. Neuroimage Clin,2015,9:564-573.
[7]	Jayadev S, Garden GA. Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders[J]. J Neuroimmune Pharmacol,2009,4(2):175-189.
[8]	Spector SA, Singh KK, Gupta S, et al. APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors[J]. AIDS,2010,24(10):1471-1479.
[9]	Morgan EE, Woods SP, Letendre SL, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders[J]. J Neurovirol,2013,19(2):150-156.
[10]	Barnes LL, Arvanitakis Z, Yu L, et al. Apolipoprotein E and change in episodic memory in blacks and whites[J]. Neuroepidemiology,2013,40(3):211-219.
[11]	Tuminello ER, Han SD. The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations[J]. Int J Alzheimers Dis,2011,2011:726197.
[12]	Ho EL, Spudich SS, Lee E, et al. Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study[J]. AIDS Res Ther,2011,8:17.
[13]	Chai Q, Jovasevic V, Malikov V, et al. HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration[J]. Nat Commun,2017,8(1):1522.
[14]	Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia[J]. Neurology,2004,63(11):2084-2090.
[15]	Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort[J]. Neurology,2004,63(5):822-827.
[16]	Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals[J]. Neurology,2007,69(24):2213-2220.
[17]	Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning[J]. J Clin Exp Neuropsychol,2003,25(2):201-215.
[18]	Brew BJ, Pemberton L, Blennow K, et al. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex[J]. Neurology,2005,65(9):1490-1492.
[19]	Gisslén M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection[J]. BMC Neurol,2009,9:63.
[20]	Valcour V, Paul R, Neuhaus J, et al. The Effects of Age and HIV on Neuropsychological Performance[J]. J Int Neuropsychol Soc,2011,17(1):190-195.
[21]	Ciccarelli N, Fabbiani M, Baldonero E, et al. Effect of aging and human immunodeficiency virus infection on cognitive abilities[J]. J Am Geriatr Soc,2012,60(11):2048-2055.
[22]	Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research[J]. BMC Neurol,2011,11:148.
[23]	Su T, Mutsaerts HJ, Caan MW, et al. Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy[J]. AIDS,2017,31(6):847-856.
[24]	Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients[J]. HIV Med,2013,14(3):136-144.
[25]	McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder[J]. Neurology,2012,78(7):485-492.
[26]	Satz P, Morgenstern H, Miller EN, et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicenter AIDS Cohort Study (MACS)[J]. J Acquir Immune Defic Syndr,1993,6(5):503-511.
[27]	Becker JT, Kingsley LA, Molsberry S, et al. Cohort Profile: Recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study[J]. Int J Epidemiol,2015,44(5):1506- 1516.
[28]	Rabkin JG, Ferrando SJ, van Gorp W, et al. Relationships among apathy, depression, and cognitive impairment in HIV/AIDS[J]. J Neuropsychiatry Clin Neurosci,2000,12(4):451-457.
[29]	Valcour V, Sithinamsuwan P, Letendre S, et al. Pathogenesis of HIV in the central nervous system[J]. Curr HIV/AIDS Rep,2011,8(1):54-61.
[30]	Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort[J]. Neurology,2010,74(16):1260-1266.
[31]	Crystal HA, Weedon J, Holman S, et al. Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women[J]. J Neurovirol,2011,17(5):469-476.
[32]	Xu Z, Asahchop EL, Branton WG, et al. MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology[J]. PLoS Pathog,2017,13(6):e1006360.
[33]	Kiko T, Nakagawa K, Tsuduki T, et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease[J]. J Alzheimers Dis,2014,39(2):253-259.

Please choose a citation manager

Content to export